United Nations calls on Gilead to create groundbreaking HIV drug that could change history

UNAIDS chief urges Gilead to expand access to groundbreaking HIV drug to end pandemic. Byanyima emphasizes potential impact and benefits.

Winnie Byanyima, head of UNAIDS, urged Gilead to allow generic manufacturing of Lenacapavir, a new HIV drug, to help end the AIDS pandemic.
Byanyima emphasized the importance of making Lenacapavir accessible in low- and middle-income nations through the Medicines Patent Pool.
She highlighted the potential impact of Lenacapavir in reaching marginalized populations and preventing new HIV infections.
Byanyima acknowledged Gilead’s contributions to HIV treatment innovation but stressed the unique benefits of Lenacapavir.
UNAIDS aims to end the AIDS pandemic by 2030 through funding, resources, and rights-based decisions, with advancements in HIV prevention and treatment.

Report from NASEM finds disparities in healthcare access for many Americans